8-K: OnKure Therapeutics Stockholders Elect Directors and Ratify KPMG as Auditor at 2025 Annual Meeting

OnKure Therapeutics, Inc. announced the successful election of two Class I directors and the ratification of KPMG LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Summary

• On May 27, 2025, OnKure Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders.
• Stockholders elected Dr. Isaac Manke and Dr. Nicholas Saccomano as Class I directors to the Company's Board of Directors.
• Dr. Manke received 4,589,481 votes For, 882,303 votes Withheld, and 1,390,547 Broker Non-Votes.
• Dr. Saccomano received 5,209,380 votes For, 262,404 votes Withheld, and 1,390,547 Broker Non-Votes.
• Both directors will serve until the 2028 Annual Meeting of Stockholders.
• Stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The ratification of KPMG LLP passed with 6,750,408 votes For, 111,715 votes Against, and 208 Abstentions, with no Broker Non-Votes.

Sentiment

Score: 7

Explanation: The document reports the successful completion of routine corporate governance matters, including the election of directors and ratification of the auditor, indicating stable operations and adherence to regulatory requirements. There are no negative or unexpected outcomes.

Positives

• The company successfully conducted its 2025 Annual Meeting of Stockholders, fulfilling a key corporate governance requirement.
• Both nominated Class I directors, Dr. Isaac Manke and Dr. Nicholas Saccomano, were successfully elected, ensuring continuity and stability on the Board.
• The selection of KPMG LLP as the independent registered public accounting firm was ratified by a significant majority of stockholders, indicating strong support for the company's financial oversight.

Future Outlook

The document does not provide specific forward-looking statements or financial guidance beyond the term of the elected directors and the fiscal year for which the auditor was ratified.

Management Comments

• Jason Leverone, Chief Financial Officer, signed the report on behalf of OnKure Therapeutics, Inc.

Industry Context

This filing is a routine corporate governance update common across all publicly traded companies, reflecting standard annual meeting procedures. It does not contain information specific to broader industry trends in the biotechnology or pharmaceutical sectors, but rather focuses on internal corporate structure and oversight.

Comparison to Industry Standards

• The election of directors and ratification of an independent accounting firm are standard corporate governance practices for publicly traded companies, aligning with typical industry benchmarks for transparency and accountability.
• The voting outcomes, with clear majorities for both proposals, suggest a stable governance environment, comparable to well-managed companies in the biotech sector like Amgen Inc. or Gilead Sciences, Inc., which typically see routine approval of such proposals.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The successful election of directors and ratification of the auditor provide assurance regarding corporate governance and financial oversight.
• Employees: No direct impact mentioned, but stable governance generally contributes to a stable corporate environment.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned, but strong governance can indirectly enhance creditworthiness.

Next Steps

• The newly elected Class I directors, Dr. Isaac Manke and Dr. Nicholas Saccomano, will serve on the Board until the 2028 Annual Meeting of Stockholders.
• KPMG LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

OnKure Therapeutics, OKUR, SEC Filing, 8-K, Annual Meeting, Stockholders Meeting, Director Election, Board of Directors, Corporate Governance, Auditor Ratification, KPMG LLP, Biotechnology, Pharmaceuticals